Who we are

Management team

Screen Shot 2017-11-07 at 6.30.33 PM.png

Jim monsoR

CEO

Jim has over 30 years of experience in drug, device, and biologic development and commercialization. Executive leadership with startups and strategic partnerships. Background in operations, product development, quality and regulatory.

Screen Shot 2017-11-07 at 6.30.42 PM.png

Robert hofmann, md

cso

Robert has over 40 years of experience as an Ophthamologist, internationally recognized clinician, teacher, inventor, scientist and author.

Screen Shot 2017-11-07 at 6.30.48 PM.png

Marcus Henschen, RN

vp

Marcus has over six years of experience in healthcare and clinical practice. His background is in healthcare and medical device startups as well as healthcare IT consulting and business development.

 

advisory board

 

Russel Pagano, Ph.D

Russ has over 20 years of experience in the medical device/biologics industry.  Russ joined Biomimetic Therapeutics in 2007 as Vice President, Clinical and Regulatory Affairs, and served in that role until January 2016. During that time he led the drive to the first approval of a combination device/biologic  in over ten years.  Prior to BioMimetic, he cofounded a clinical and regulatory consulting company based in Washington DC. Russ started his career working 7 years for the FDA, overseeing device filing reviews and product approvals.

Mark Cherney

Mark has more than forty years of healthcare industry expertise as both a corporate executive, entrepreneur, board member, and advisor to private equity. He has extensive experience in services segment including oncology, urology, diagnostic imaging, allied staffing, managed care, IT services, pharmacy distribution, home-health, and physician practice management.

George Dunbar

George has extensive healthcare and life sciences operating experience, and has served as an advisor, Director, or CEO with private and public companies in diagnostics, specialty pharma, cell therapy, and biologics. He is the managing partner of The Dunbar Group providing management services to the life sciences. The most recent  assignment was CEO of  Isto Biologics, Prior to ISTO Technologies, he served as a Venture Partner with Arboretum Ventures, and a director of four portfolio life science companies - two as executive chairman. He has held senior leadership positions with Ares-Serono (now Merck-Serono) and Amersham International (now GE Healthcare).

Stayko Staykov

Stayko has over fifteen years of experience in entrepreneurship, strategic asset management and advising in the areas of strategy development, mergers & acquisitions, intellectual property assets, technology licensing, and leadership development. He is also co-founder of Venture Grove and a director for Zyxogen.